Thomas J H
University of Kansas Medical Center, Department of Surgery, Kansas City 66103.
Am J Surg. 1990 Dec;160(6):547-51. doi: 10.1016/s0002-9610(05)80743-3.
Thrombosis and its major sequela, embolism, continue to contribute significantly to morbidity and mortality, both as primary disorders and as complications of other systemic systems. The understanding of the etiology of thromboembolism and the role of platelets, endothelium, and the plasma proteins in the development of thrombotic disorders has recently improved. Other blood cells, in particular neutrophils, have been suggested as possible mediators of thrombosis in clinical disorders characterized by decreased capillary blood flow. Newer imaging techniques such as duplex scanning have improved the accuracy and ease of diagnosis. Thrombolytic therapy is a more physiologic approach to the management of thrombosis, but its role is limited by systemic fibrinolysis. The development of fibrin-specific agents and better delivery techniques in combination with thromboembolectomy and anticoagulation should improve the management of patients with thrombosis.
血栓形成及其主要后果——栓塞,无论是作为原发性疾病还是作为其他全身系统的并发症,都继续对发病率和死亡率产生重大影响。最近,人们对血栓栓塞的病因以及血小板、内皮细胞和血浆蛋白在血栓形成性疾病发展中的作用有了更深入的了解。在以毛细血管血流减少为特征的临床疾病中,其他血细胞,特别是中性粒细胞,被认为可能是血栓形成的介质。诸如双功扫描等更新的成像技术提高了诊断的准确性和便捷性。溶栓治疗是一种更符合生理的血栓管理方法,但其作用受到全身纤溶的限制。纤维蛋白特异性药物的开发以及更好的给药技术与血栓切除术和抗凝治疗相结合,应能改善血栓患者的管理。